Industry / Spain
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
GSK Seeks Regulatory Advice To Strategise Drug Development
July 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
New GlaxoSmithKline (GSK) CEO Andrew Witty has reaffirmed the company's commitment to developing innovative therapies, and dispelled rumours that a foray into the generics industry may be part of company strategy. Speaking in an interview with the Wall Street Journal, Witty called the generics market a 'tough world to play in', and said that the company had 'far better ways of creating